# Iambic Therapeutics, Inc. Common Stock (IAM)

> Source: Nexqual · https://nexqual.com/IAM · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Iambic Therapeutics, Inc. Common Stock (IAM), nexqual.com/IAM" · informational, not investment advice.

**Price:** USD 18.91 (+18.19% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 18.91 · day 16.15–19.7 · 52w 16.15–19.7 · market cap null · NMS

## Key facts
- Analysts: None.
- Total return with dividends: 5Y +0.0% vs S&P 500 +85.1%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 5Y (from 2026-10-12) |
|---|---|
| Total return | +0.0% |
| S&P 500 (SPY) | +85.1% |
| Per year | — |
| Volatility (annualized) | 0.0% |
| Max drawdown | +0.0% (→) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IAM · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt